arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

Steven Novick

19 papers · 2002–2023

2002: 12003: 02004: 02005: 12006: 02007: 02008: 12009: 02010: 02011: 12012: 12013: 02014: 22015: 12016: 12017: 02018: 32019: 32020: 22021: 02022: 12023: 1
2002peak 3 in 20182023

Frequent co-authors

Papers

showing 1–19 of 19 RSS

Corrected Score Estimation via Complex Variable Simulation Extrapolation

Steven Novick, Leonard A. Stefanski

Statistics and Probability · Journal of the American Statistical Association · · cited 54× · DOI ↗ · more like this ·

A Monte Carlo method of computing unbiased estimating equations for the analysis of data measured with error is described. Asymptotic distribution results are obtained for estimators derived from the Monte Carlo estimating equations. The method is illustrated with examples, applications, and simulation studies. The Monte Carlo estimating equations are corrected scores in the sense of Nakamura, and the proposed methods are closely related to the simulation method described by Cook and Stefanski.

DOSE-L1000: unveiling the intricate landscape of compound-induced transcriptional changes

Junmin Wang, Steven Novick

Computational Theory and Mathematics · Bioinformatics · · cited 9× · DOI ↗ · more like this ·

MOTIVATION: The LINCS L1000 project has collected gene expression profiles for thousands of compounds across a wide array of concentrations, cell lines, and time points. However, conventional analysis methods often fall short in capturing the rich information encapsulated within the L1000 transcriptional dose-response data. RESULTS: We present DOSE-L1000, a database that unravels the potency and efficacy of compound-gene pairs and the intricate landscape of compound-induced transcriptional changes. Our study uses the fitting of over 140 million generalized additive models and robust linear models, spanning the complete spectrum of compounds and landmark genes within the LINCS L1000 database. This systematic approach provides quantitative insights into differential gene expression and the potency and efficacy of compound-gene pairs across diverse cellular contexts. Through examples, we…

A fast and reliable test for parallelism in bioassay

Steven Novick, Harry Yang

Statistics and Probability · Journal of Biopharmaceutical Statistics · · cited 5× · DOI ↗ · more like this ·

Parallelism in bioassay is a synonym of similarity between two concentration–response curves. Before the determination of relative potency in bioassays, it is necessary to test for and claim parallelism between the pair of concentration–response curves of reference standard and test sample. Methods for parallelism testing include p-value-based significance tests and interval-based equivalence tests. Most of the latter approaches make statistical inference about the equivalence of parameters of the concentration–response curve models. An apparent drawback of such methods is that equivalence in model parameters does not guarantee similarity between the reference and test sample. In contrast, a Bayesian method was recently proposed that directly tests the parallelism hypothesis that the concentration–response curve of the test sample is a horizontal shift of that of the reference. In other…

Detecting bliss synergy in in vivo combination studies with a tumor kinetic model

Wei Zhao, Paolo Vicini, Steven Novick +9 more

Modeling and Simulation · Pharmaceutical Statistics · · cited 4× · DOI ↗ · more like this ·

Linear models are generally reliable methods for analyzing tumor growth in vivo, with drug effectiveness being represented by the steepness of the regression slope. With immunotherapy, however, not all tumor growth follows a linear pattern, even after log transformation. Tumor kinetics models are mechanistic models that describe tumor proliferation and tumor killing macroscopically, through a set of differential equations. In drug combination studies, although an additional drug-drug interaction term can be added to such models, however, the drug interactions suggested by tumor kinetics models cannot be translated directly into synergistic effects. We have developed a novel statistical approach that simultaneously models tumor growth in control, monotherapy, and combination therapy groups. This approach makes it possible to test for synergistic effects directly and to compare such…

Effect of a statistical outlier in potency bioassays

Perceval Sondag, Lingmin Zeng, Binbing Yu +4 more

Statistics and Probability · Pharmaceutical Statistics · · cited 4× · DOI ↗ · more like this ·

The USP<1032> guidelines recommend the screening of bioassay data for outliers prior to performing a relative potency (RP) analysis. The guidelines, however, do not offer advice on the size or type of outlier that should be removed prior to model fitting and calculation of RP. Computer simulation was used to investigate the consequences of ignoring the USP<1032> guidance to remove outliers. For biotherapeutics and vaccines, outliers in potency data may result in the false acceptance/rejection of a bad/good lot of drug product. Biological activity, measured through a potency bioassay, is considered a critical quality attribute in manufacturing. If the concentration-response potency curve of a test sample is deemed to be similar in shape to that of the reference standard, the curves are said to exhibit constant RP, an essential criterion for the interpretation of a RP. One or more…

A Bayesian Approach to Show Assay Equivalence with Replicate Measurements Over a Specified Response Range

Steven Novick, Karen Chiswell, John J. Peterson

Statistics and Probability · Statistics in Biopharmaceutical Research · · cited 4× · DOI ↗ · more like this ·

Drug discovery scientists routinely develop and use in-vitro assays; for example, to identify “hits,” or to quantify the efficacious concentrations of compounds in a lead series. New and improved assays are developed to replace existing ones as the new assays may be cheaper, faster, or easier to use. An existing assay typically cannot be replaced until the new format is determined to produce equivalent measurements to the original on a test set of compounds with a diverse range of activity. In this article we propose two definitions for assessing assay equivalence across a range of responses, and apply Bayesian methods to estimate the probability of assay equivalence. Data are modeled via orthogonal regression for the case where the relative variability of the two assays is unknown a priori, and replicate measurements for each assay and compound are sufficient to identify the full set…

A comparison of statistical methods for animal oncology studies

Tianhui Zhang, Steven Novick

Modeling and Simulation · Pharmaceutical Statistics · · cited 3× · DOI ↗ · more like this ·

In pre-clinical oncology studies, tumor-bearing animals are treated and observed over a period of time in order to measure and compare the efficacy of one or more cancer-intervention therapies along with a placebo/standard of care group. A data analysis is typically carried out by modeling and comparing tumor volumes, functions of tumor volumes, or survival. Data analysis on tumor volumes is complicated because animals under observation may be euthanized prior to the end of the study for one or more reasons, such as when an animal's tumor volume exceeds an upper threshold. In such a case, the tumor volume is missing not-at-random for the time remaining in the study. To work around the non-random missingness issue, several statistical methods have been proposed in the literature, including the rate of change in log tumor volume and partial area under the curve. In this work, an…

The current state of Bayesian methods in nonclinical pharmaceutical statistics: Survey results and recommendations from the <scp>DIA</scp>/<scp>ASA‐BIOP</scp> Nonclinical Bayesian Working Group

Paul Faya, Perceval Sondag, Steven Novick +4 more

Statistics and Probability · Pharmaceutical Statistics · · cited 3× · DOI ↗ · more like this ·

The use of Bayesian methods to support pharmaceutical product development has grown in recent years. In clinical statistics, the drive to provide faster access for patients to medical treatments has led to a heightened focus by industry and regulatory authorities on innovative clinical trial designs, including those that apply Bayesian methods. In nonclinical statistics, Bayesian applications have also made advances. However, they have been embraced far more slowly in the nonclinical area than in the clinical counterpart. In this article, we explore some of the reasons for this slower rate of adoption. We also present the results of a survey conducted for the purpose of understanding the current state of Bayesian application in nonclinical areas and for identifying areas of priority for the DIA/ASA-BIOP Nonclinical Bayesian Working Group. The survey explored current usage, hurdles…

A Novel Bayesian Method for Efficacy Assessment in Animal Oncology Studies

Steven Novick, Kris F. Sachsenmeier, Ching Ching Leow +2 more

Statistics and Probability · Statistics in Biopharmaceutical Research · · cited 3× · DOI ↗ · more like this ·

In pre-clinical oncology studies, the investigator often compares efficacy of two or more treatments on tumor-bearing animals over a period of time. This is accomplished either through comparison of tumor volumes at various time points or overall survival. Due to ethical concerns, animals are euthanized before the end of the study whenever their tumor volumes reach a prespecified limit, the loss of bodyweight is beyond 20% or severely ulcerated tumors are observed. The traditional cross time-point tumor-size comparisons should not be performed when animals leave the study in a nonrandom nature. Survival analysis may alternatively be carried out to compare the time-to-euthanasia or natural death across treatment groups. As a result of government regulations, however, animal survival studies are hampered by small-sample sizes, often making statistical inference of survival data difficult.…

Content Uniformity Testing

Steven Novick, Buffy Hudson‐Curtis

Artificial Intelligence · · cited 2× · DOI ↗ · more like this ·

This chapter discusses the United States Pharmacopeia guidelines, ASTM E2810 and PTI-TOST are provided along with the Bayesian counterparts and extensions. Content uniformity is a measure of the amount of active pharmaceutical ingredient in the units of a batch of drug product. Though currently accepted, content uniformity tests by regulatory agencies are Bayesian in nature. Bayesian approaches can be extremely useful in assessing batch and process performance against these tests as well as in addressing more complex data structures when applying these tests. As for issues with informative priors, we agree that one must take care not to overwhelm the assayed results from sampled units of a new batch with historical information. On the other hand, there should also be room to debate the level of historical data that may be incorporated when declaring whether or a batch exhibits a content…

Data-Driven Prior Distributions for A Bayesian Phase-2 COPD Dose-Finding Clinical Trial

Steven Novick, Shuyen Ho, Nicky Best

Statistics and Probability · Statistics in Biopharmaceutical Research · · cited 2× · DOI ↗ · more like this ·

The prior distribution reflects knowledge and uncertainty of the modeled parameters. Determining the prior distribution for a dose-finding clinical trial can be influential in its design and analysis. Using the planning of a phase 2 trial for COPD with a dose-response curve as a case study, we illustrate the use of relevant historical data for the nonlinear curve mean-model parameters as well as consideration for terms to characterize between-trial and within-trial variability. Through a predictive inference exercise, a data-driven informative prior distribution is constructed for the future study. We share our strategies on how to obtain informative Bayesian priors for both design and analysis of dose-finding clinical trials using relevant historical data and deal with the associated issues.

A Generalized Pivotal Quantity Approach to the Parametric Tolerance Interval Test for Dose Content Uniformity Batch Testing

Richard A. Lewis, Steven Novick

Statistics and Probability · Statistics in Biopharmaceutical Research · · cited 2× · DOI ↗ · more like this ·

The Food and Drug Administration (FDA) has proposed a parametric tolerance interval test (PTIT) for batch-release testing of inhalation devices. The proposed test examines dose uniformity based on several inhalation units from a batch, with two observations per unit. An underlying assumption is that the observations are a random sample from a univariate normal distribution. Because there are two observations per unit, it may be more appropriate to model the data as stemming from a bivariate normal distribution. We take a bivariate approach and use generalized confidence interval methodology to derive a parametric tolerance interval for the distribution of doses within a batch. We then use Monte Carlo simulation to compare results based on this bivariate approach with those based on the FDA-proposed PTIT.

Bayesian Estimation of Sample Size and Power

Harry Yang, Steven Novick

Statistics and Probability · · cited 1× · DOI ↗ · more like this ·

This chapter deals with sample size determination for the purpose of testing hypotheses. Sample size calculations based on Bayesian concepts are discussed through three examples, one related to product lot release and the other two regarding futility and interim analysis in sequential trials. Sample size determination is an important aspect in study design, especially in the planning of clinical trials due to regulatory requirements. The “decision-theoretic Bayesian” approach determines a sample size that maximizes a utility function for the cost of the study and potential benefit of the new intervention or improved process. Futility represents an important extension of the Bayesian viewpoint of sample size/power calculations. The term “futility” refers to unlikeliness for the trial to achieve statistical significance for its primary endpoints. The statistical power of a test is the…

Testing drug additivity based on monotherapies

Harry Yang, Steven Novick, Wei Zhao

Statistics and Probability · Pharmaceutical Statistics · · cited 1× · DOI ↗ · more like this ·

Under the Loewe additivity, constant relative potency between two drugs is a sufficient condition for the two drugs to be additive. Implicit in this condition is that one drug acts like a dilution of the other. Geometrically, it means that the dose-response curve of one drug is a copy of another that is shifted horizontally by a constant over the log-dose axis. Such phenomenon is often referred to as parallelism. Thus, testing drug additivity is equivalent to the demonstration of parallelism between two dose-response curves. Current methods used for testing parallelism are usually based on significance tests for differences between parameters in the dose-response curves of the monotherapies. A p-value of less than 0.05 is indicative of non-parallelism. The p-value-based methods, however, may be fundamentally flawed because an increase in either sample size or precision of the assay used…

Drug Combination Synergy

Harry Yang, Steven Novick, Wei Zhao

Statistics and Probability · · cited 1× · DOI ↗ · more like this ·

In drug combination research, the primary goal is to assess whether drugs used in combination produce synergistic effect. Over the past decades, many statistical methods have been developed. This chapter provides an introduction to methods used for drug synergy assessment. Also discussed in the chapter is a novel Bayesian method for drug additivity evaluation based on monotherapy data.

A new PK equivalence test for a bridging study

Steven Novick, Xiang Zhang, Harry Yang

Statistics and Probability · Journal of Biopharmaceutical Statistics · · cited 0× · DOI ↗ · more like this ·

In a bridging study, the plasma drug concentration-time curve is generally used to assess bioequivalence between the two formulations. Selected pharmacokinetic (PK) parameters including the area under the concentration-time curve, the maximum plasma concentration or peak exposure (Cmax), and drug half-life (T1/2) are compared to ensure comparable bioavailability of the two formulations. Comparability in these PK parameters, however, does not necessarily imply equivalence of the entire concentration-time profile. In this article, we propose an alternative metric of equivalence based on the maximum difference between PK profiles of the two formulations. A test procedure based on Bayesian analysis and accounting for uncertainties in model parameters is developed. Through both theoretical derivation and empirical simulation, it is shown that the new method provides better control over…

Drug Combination Design Strategies

Steven Novick, John J. Peterson Maiying Kong, J. Jack Lee

Computational Theory and Mathematics · · cited 0× · DOI ↗ · more like this ·

A thorough examination of the experimental design is undertaken for the various approaches to drug-combination analysis. Depending on available resources, the investigator may be able to produce an experiment that can support tting a response-surface model or might be limited to a simple analytical procedure. This chapter does not claim to provide a complete listing of every possible experimental design, but rather attempts to furnish guidance for the practitioner in choosing an experimental design framework.

Monte Carlo Estimation of g(µ) from Normally Distributed Data with Applications

Leonard A. Stefanski, Steven J. Novick, Viswanath Devanarayan

Statistics and Probability · · cited 0× · OpenAlex ↗ · more like this ·

Abstract We derive Monte Carlo-amenable solutions to the problem of unbiased estimation of a nonlinear function of the mean of a normal distribution. For most nonlinear functions the maximum likelihood estimator is biased. Our method yields a Monte Carlo approximation to the uniformly minimum variance unbiased estima-tor for a wide class of nonlinear functions. Applications to problems arising in the analysis of data measured with error and the secondary analysis of estimated data are described.